ROVI acquires Falithrom® for the German market

ROVI will pay Hexal nine million euros for the product, the net sales of which totalled close to 3.5 million euros in 2017


Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”) has announced the purchase of Falithrom®, which was owned by Hexal AG (“Hexal”), a company belonging to the Sandoz division of Novartis, to be directly marketed by ROVI in Germany.

Falithrom® is used for the prevention and treatment of thromboembolic disease including venous thrombosis, thromboembolism, and pulmonary embolism as well as for the prevention of ischemic stroke in patients with atrial fibrillation (AF).

According to IQVIA, the 2017 net sales of the product in Germany totalled around 3.5 million euros. ROVI will pay Hexal nine million euros for the product.

Under this agreement, Falithrom® will be directly marketed by ROVI in Germany as soon as the administrative processes to authorize the transfer of the marketing authorization are completed before the German Federal Institute for Drugs and Medical Devices (BfArM).

Juan López-Belmonte Encina, ROVI’s CEO, commented: “With Falithrom®, ROVI reinforces its position in the anticoagulant market in Germany, the largest market in Europe, as part of its strategy to become a European player. Likewise, Falithrom® fully complements our existing portfolio and will be immediately accretive to our Germany subsidiary’s earnings”.

No votes yet
 
Related
ROVI REPORTS OPERATING REVENUE GROWTH OF 31% AND NET PROFIT GROWTH OF 58%   Operating revenue increased by 31% to 380.4...
3 min
27/07/2022
Madrid, 19th July 2022 The European Investment Bank (EIB) is providing Laboratorios Farmacéuticos Rovi (ROVI) with a new EUR 50 million...
4 min
19/07/2022
ROVI REPORTS OPERATING REVENUE GROWTH OF 57% AND NET PROFIT GROWTH OF 123% • Operating revenue increased by 57% to 205.6 million euros...
2 min
11/05/2022